B7-33
B7-33Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for B7-33.
Shown in preclinical models to reduce cardiac fibrosis and collagen deposition
Attenuates myofibroblast activation and differentiation in tissue injury models
Biased RXFP1 agonist preferentially activates ERK1/2 over cAMP signaling
May limit adverse cardiac remodeling after myocardial infarction in rodents
Reduces renal fibrosis in preclinical kidney injury studies
May decrease TGF-beta-driven profibrotic signaling pathways
Less vasodilatory effect than full-length relaxin, potentially lower hypotension risk
Supports matrix remodeling and reduced scar formation in animal studies
Single-chain design facilitates chemical synthesis and mechanistic study
This peptide's combination-safety and interaction data below always stays visible, regardless of membership.
Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.
Discussions
Community discussions are coming soon.